|
|
(29 intermediate revisions by the same user not shown) |
Line 1: |
Line 1: |
| {{ Poster }} | | {{ Poster }} |
| | | |
− | <html><head> | + | <html><head></head><body> |
| + | |
| + | |
| + | |
| <!-- <link rel="stylesheet" href="../css/styles.css"> --> | | <!-- <link rel="stylesheet" href="../css/styles.css"> --> |
| <style> | | <style> |
Line 14: |
Line 17: |
| } | | } |
| .sponsor-images { | | .sponsor-images { |
− | display: flex; | + | flex-flow: wrap; |
| + | text-align: center; |
| } | | } |
| .sponsor-images img { | | .sponsor-images img { |
| margin: 10px; | | margin: 10px; |
| + | width: 155px; |
| + | } |
| + | .collab-images { |
| + | flex-flow: wrap; |
| + | text-align: center; |
| + | } |
| + | .collab-images img { |
| + | margin: 10px; |
| + | width: 155px; |
| } | | } |
| .flex-row { | | .flex-row { |
Line 29: |
Line 42: |
| .img-third { | | .img-third { |
| width: 30%; | | width: 30%; |
− | margin: 15px; | + | min-width: 160px; |
− | border-radius: 4px; | + | max-width: 160px; |
| + | margin: auto 10px; |
| + | } |
| + | .row-third { |
| + | width: 28%; |
| + | margin: 10px; |
| + | text-align: left; |
| } | | } |
| table, | | table, |
Line 37: |
Line 56: |
| border: 1px solid black; | | border: 1px solid black; |
| border-collapse: collapse; | | border-collapse: collapse; |
| + | } |
| + | td { |
| + | text-align: center; |
| } | | } |
| * { | | * { |
| font-family: "Montserrat" !important; | | font-family: "Montserrat" !important; |
| + | } |
| + | |
| + | ::-moz-selection { |
| + | /* Code for Firefox */ |
| + | background: #7bb8fa50 !important; |
| + | } |
| + | |
| + | ::selection { |
| + | background: #7bb8fa50 !important; |
| } | | } |
| | | |
Line 98: |
Line 129: |
| /* FONTS END */ | | /* FONTS END */ |
| </style> | | </style> |
− | </head> | + | |
− | <body> | + | |
| <div class="page_wrapper"> | | <div class="page_wrapper"> |
| <div class="poster_w content"> | | <div class="poster_w content"> |
Line 112: |
Line 143: |
| <div class="text"> | | <div class="text"> |
| <h5>Presented by: Team IIT Roorkee</h5> | | <h5>Presented by: Team IIT Roorkee</h5> |
| + | <br/> |
| + | Team: Sanjeevani Marcha<sup>1</sup>, Muskaan |
| + | Bhambri<sup>1</sup>, Harkirat Singh Arora<sup>1</sup>, Kushagra |
| + | Rustagi<sup>1</sup>, Pradum Kumar<sup>1</sup>, Yash |
| + | Aggrawal<sup>1</sup>, Nitish Verma<sup>1</sup>, Siddharth |
| + | FItwe<sup>1</sup>, Tishee Natani<sup>1</sup>, Kartikey |
| + | Kansal<sup>1</sup>, Kanishk Sugotra<sup>1</sup>, Lakshya |
| + | Jain<sup>1</sup>, Mihir Sachdeva<sup>1</sup>, Dr Siva Ram |
| + | Uppalapati<sup>2</sup>, Somok Bhowmik<sup>2</sup>, Professor |
| + | Naveen K. Navani<sup>2</sup>, Professor Ranjana Pathania<sup>3</sup> |
| + | <br/> |
| + | <h4><sup>1</sup>iGEM Student team member</h4> |
| + | <h4><sup>2</sup>iGEM Advisor</h4> |
| + | <h4><sup>3</sup>iGEM Primary PI</h4> |
| + | <br/><br/> |
| + | <b>Abstract</b> |
| + | <br/> |
| Our project is aimed at creating novel antibacterial protein | | Our project is aimed at creating novel antibacterial protein |
| complexes called Seekercins, designed to specifically bind and | | complexes called Seekercins, designed to specifically bind and |
Line 122: |
Line 170: |
| relationships between resistance genes so as to resensitize them | | relationships between resistance genes so as to resensitize them |
| to antibiotics. Validation will be done experimentally, | | to antibiotics. Validation will be done experimentally, |
− | targeting the pathogen Acinetobacter baumannii, and production | + | targeting the pathogen <i>Acinetobacter baumannii</i>, and |
− | will be done in E. coli. | + | production will be done in <i>E. coli.</i> <br/><br/> |
− | <br/><br/>
| + | |
− | Team: Sanjeevani Marcha<sup>1</sup>, Muskaan Bhambri<sup>1</sup>, Harkirat Singh Arora<sup>1</sup>,
| + | |
− | Kushagra Rustagi<sup>1</sup>, Pradum Kumar<sup>1</sup>, Yash Aggrawal<sup>1</sup>, Nitish Verma<sup>1</sup>,
| + | |
− | Siddharth FItwe<sup>1</sup>, Tishee Natani<sup>1</sup>, Kartikey Kansal<sup>1</sup>, Kanishk Sugotra<sup>1</sup>,
| + | |
− | Lakshya Jain<sup>1</sup>, Mihir Sachdeva<sup>1</sup>, Dr Siva Ram Uppalapati<sup>2</sup>, Somok Bhowmik<sup>2</sup>,
| + | |
− | Professor Naveen K. Navani<sup>2</sup>, Professor Ranjana Pathania<sup>3</sup>
| + | |
− | <br/><br/>
| + | |
− | <h4><sup>1</sup>iGEM Student team member</h4>
| + | |
− | <br/>
| + | |
− | <h4><sup>2</sup>iGEM Advisor</h4>
| + | |
− | <br/>
| + | |
− | <h4><sup>3</sup>iGEM Primary PI</h4>
| + | |
− | <br/><br/>
| + | |
| </div> | | </div> |
| </div> | | </div> |
Line 159: |
Line 194: |
| <b>45.6% to 60.9%</b>, reaching <b>84.3%</b> when caused by | | <b>45.6% to 60.9%</b>, reaching <b>84.3%</b> when caused by |
| <b>XDR <i>A. baumannii</i></b>. <br/><br/> | | <b>XDR <i>A. baumannii</i></b>. <br/><br/> |
− | As a In our solution, we use pyocins, which are high molecular | + | As a solution, we use pyocins, which are high molecular |
| weight bactericidal protein complexes produced by | | weight bactericidal protein complexes produced by |
| <i>P. aeruginosa</i>. Pyocins attach to receptors on the | | <i>P. aeruginosa</i>. Pyocins attach to receptors on the |
Line 180: |
Line 215: |
| <div class="text"> | | <div class="text"> |
| <h3>Inspiration</h3> | | <h3>Inspiration</h3> |
− | Interviews with doctors and ICU specialists made us realise it | + | Interviews with doctors and ICU specialists made us realise |
− | clear the necessity for alternative treatments for drug | + | the necessity for alternative treatments for drug |
| resistant infections in the face of rapid AMR development. | | resistant infections in the face of rapid AMR development. |
| <br/><br/> | | <br/><br/> |
Line 243: |
Line 278: |
| <br/><br/> | | <br/><br/> |
| | | |
− | After literature review of existing Acinetobacter baumannii | + | After literature review of existing |
| + | <i>Acinetobacter baumannii</i> |
| phages, phage AP22 was selected as a suitable candidate for its | | phages, phage AP22 was selected as a suitable candidate for its |
| large lytic spectrum. | | large lytic spectrum. |
Line 259: |
Line 295: |
| aligned with the last 134 amino acids of R2 pyocin tail fiber. | | aligned with the last 134 amino acids of R2 pyocin tail fiber. |
| We replaced the lectin-fold head region of R-pyocin tail fiber | | We replaced the lectin-fold head region of R-pyocin tail fiber |
− | with a similar lectin-fold binding domain from A. baumannii | + | with a similar lectin-fold binding domain from |
| + | <i>A. baumannii</i> |
| specific bacteriophage AP22 tail fiber which naturally targets | | specific bacteriophage AP22 tail fiber which naturally targets |
| these bacteria. Models of the fusion tail fiber were verified | | these bacteria. Models of the fusion tail fiber were verified |
Line 280: |
Line 317: |
| | | |
| As a chassis we chose to produce them in | | As a chassis we chose to produce them in |
− | <i>Escherichia coli</i>, specifically strain BL21(DE3).As an | + | <i>Escherichia coli</i>, strain BL21(DE3).As an |
| expression vector, we chose pET-28 a from Novagen which contains | | expression vector, we chose pET-28 a from Novagen which contains |
− | a T7 promoter and lac operator, allowing | + | a T7 promoter and <i>lac operator</i>, allowing |
− | IPTG-controllableinduced protein expression. | + | IPTG-induced protein expression. |
| | | |
| <br/><br/> | | <br/><br/> |
Line 324: |
Line 361: |
| </div> | | </div> |
| </div> | | </div> |
| + | <br/><br/> |
| <div class="flex-row"> | | <div class="flex-row"> |
| <div class="img-third"> | | <div class="img-third"> |
Line 342: |
Line 380: |
| </div> | | </div> |
| </div> | | </div> |
| + | <br/><br/> |
| <div class="flex-row"> | | <div class="flex-row"> |
| <div class="img-third"> | | <div class="img-third"> |
Line 373: |
Line 412: |
| | | |
| We have introduced two new basic Parts to the iGEM registry as a | | We have introduced two new basic Parts to the iGEM registry as a |
− | contribution for us ebay future iGEM teams. | + | contribution for us future iGEM teams. |
| | | |
| <br/> | | <br/> |
Line 392: |
Line 431: |
| <br/> | | <br/> |
| | | |
− | <b>BASIC PARTS:</b> | + | <b>COMPOSITE PARTS:</b> |
| | | |
| <br/> | | <br/> |
Line 402: |
Line 441: |
| Part:BBa_K3564102 : Composite of BBa_K3564001 and BBa_K3564002 | | Part:BBa_K3564102 : Composite of BBa_K3564001 and BBa_K3564002 |
| that expresses a Seekercin, i.e. a pyocin targeted to | | that expresses a Seekercin, i.e. a pyocin targeted to |
− | specifically Bind and kill Acinetobacter baumannii | + | specifically Bind and kill <i>Acinetobacter baumannii</i> |
− | <br/> | + | <br/><br/> |
| Characterization for the composite parts would be updated once | | Characterization for the composite parts would be updated once |
| the experiments planned are completed post-pandemic. | | the experiments planned are completed post-pandemic. |
Line 426: |
Line 465: |
| <li class="wiki-li"> | | <li class="wiki-li"> |
| The team received insightful facts on the situation of | | The team received insightful facts on the situation of |
− | AMR infections inside ICUs during CoVID-19. | + | AMR infections inside ICUs during COVID-19. |
| </li> | | </li> |
| <li class="wiki-li"> | | <li class="wiki-li"> |
| We got to know that doctors use IL-6 antagonists and | | We got to know that doctors use IL-6 antagonists and |
− | immunosuppressants for CoVID Regulation. | + | immunosuppressants for COVID Regulation. |
| </li> | | </li> |
| <li class="wiki-li"> | | <li class="wiki-li"> |
Line 505: |
Line 544: |
| reached out to huge masses and successfully increased the | | reached out to huge masses and successfully increased the |
| awareness quotient of people to an impressive 35 - 40% extent. | | awareness quotient of people to an impressive 35 - 40% extent. |
− | <div class="sponsor-images" style="display: flex; flex-flow: wrap"> | + | <div class="collab-images"> |
| <img alt="" src="https://static.igem.org/mediawiki/2020/3/3e/T--IIT_Roorkee--Poster_images--poster-content--Poster_Collab1.PNG"/> | | <img alt="" src="https://static.igem.org/mediawiki/2020/3/3e/T--IIT_Roorkee--Poster_images--poster-content--Poster_Collab1.PNG"/> |
| <img alt="" src="https://static.igem.org/mediawiki/2020/1/18/T--IIT_Roorkee--Poster_images--poster-content--Poster_Collab2.png"/> | | <img alt="" src="https://static.igem.org/mediawiki/2020/1/18/T--IIT_Roorkee--Poster_images--poster-content--Poster_Collab2.png"/> |
Line 538: |
Line 577: |
| by 2030. So playing our part, we have contributed to three of | | by 2030. So playing our part, we have contributed to three of |
| such goals (as mentioned below) through our project Pyomancer. | | such goals (as mentioned below) through our project Pyomancer. |
− | <div class="sponsor-images" style="text-align: center"> | + | <br/><br/> |
− | <div class="section third"> | + | <div class="flex-row" style="text-align: center"> |
| + | <div class="row-third"> |
| <img alt="" src="https://static.igem.org/mediawiki/2020/0/0d/T--IIT_Roorkee--Poster_images--poster-content--SDG1.png"/> | | <img alt="" src="https://static.igem.org/mediawiki/2020/0/0d/T--IIT_Roorkee--Poster_images--poster-content--SDG1.png"/> |
| + | <br/> |
| + | <b>Target 3.2</b> |
| + | <br/> |
| <ul class="wiki-ul"> | | <ul class="wiki-ul"> |
| <li class="wiki-li"> | | <li class="wiki-li"> |
Line 550: |
Line 593: |
| </ul> | | </ul> |
| </div> | | </div> |
− | <div class="section third"> | + | <div class="row-third"> |
− | <img alt="" src="https://static.igem.org/mediawiki/2020/c/c8/T--IIT_Roorkee--Poster_images--poster-content--SDG2.jpg"/> | + | <img alt="" src="https://static.igem.org/mediawiki/2020/c/c7/T--IIT_Roorkee--Poster_images--poster-content--SDG3.png"/> |
| + | <br/> |
| + | <b>Target 4.5</b> |
| + | <br/> |
| <ul class="wiki-ul"> | | <ul class="wiki-ul"> |
| <li class="wiki-li"> | | <li class="wiki-li"> |
Line 559: |
Line 605: |
| </ul> | | </ul> |
| </div> | | </div> |
− | <div class="section third"> | + | <div class="row-third"> |
− | <img alt="" src="https://static.igem.org/mediawiki/2020/c/c7/T--IIT_Roorkee--Poster_images--poster-content--SDG3.png"/> | + | <img alt="" src="https://static.igem.org/mediawiki/2020/c/c8/T--IIT_Roorkee--Poster_images--poster-content--SDG2.jpg"/> |
| + | <br/> |
| + | <b>Target 17.16 & 17.17</b> |
| + | <br/> |
| <ul class="wiki-ul"> | | <ul class="wiki-ul"> |
| <li class="wiki-li"> | | <li class="wiki-li"> |
Line 676: |
Line 725: |
| <div class="text"> | | <div class="text"> |
| <p><b> TailScout </b></p> | | <p><b> TailScout </b></p> |
− | <br/><br/>
| |
| We have developed a web application <b>TailScout</b> which | | We have developed a web application <b>TailScout</b> which |
| generates secondary structure of the Engineered pyocin by taking | | generates secondary structure of the Engineered pyocin by taking |
Line 693: |
Line 741: |
| <br/> | | <br/> |
| | | |
− | <br/><br/><br/>
| |
| Backend Workflow: | | Backend Workflow: |
| | | |
− | <br/><br/><br/> | + | <br/><br/> |
| <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/0/02/T--IIT_Roorkee--Poster_images--poster-content--poster_Software.png"/> | | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/0/02/T--IIT_Roorkee--Poster_images--poster-content--poster_Software.png"/> |
| </div> | | </div> |
Line 736: |
Line 783: |
| | | |
| <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/d/db/T--IIT_Roorkee--Poster_images--poster-content--poster_implementation_1.jpg"/> | | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/d/db/T--IIT_Roorkee--Poster_images--poster-content--poster_implementation_1.jpg"/> |
− | </div>
| + | <div class=""> |
− | <div class="">
| + | Surfactant consists of 80-85 % phospholipids, 5-10 % neutral |
− | Surfactant consists of 80-85 % phospholipids, 5-10 % neutral
| + | lipids, and 8-10 % protein, with 5-6 % of the four specific |
− | lipids, and 8-10 % protein, with 5-6 % of the four specific
| + | proteins of surfactant. Broadly, the formulation has the |
− | proteins of surfactant. Broadly, the formulation has the
| + | following structure: |
− | following structure:
| + | |
− | </div>
| + | |
− | <br/><br/>
| + | |
− | <div class="">
| + | |
− | <div class="table-responsive">
| + | |
− | <table class="table table-hover table-bordered">
| + | |
− | <thead class="thead-dark">
| + | |
− | <tr>
| + | |
− | <th scope="col">
| + | |
− | <b>Mucolytics:</b> Carbocisteine, Erdosteine.
| + | |
− | </th>
| + | |
− | <th scope="col">
| + | |
− | <b>Bronchodilators:</b>Beta-2 agonists,
| + | |
− | Anticholinergics, Theophylline
| + | |
− | </th>
| + | |
− | </tr>
| + | |
− | </thead>
| + | |
− | <tbody>
| + | |
− | <tr>
| + | |
− | <td>Seekercin A</td>
| + | |
− | <td>di-Palmitoylphosphatidylcholine (DPPC)</td>
| + | |
− | </tr>
| + | |
− | <tr>
| + | |
− | <td>Seekercin B</td>
| + | |
− | <td>Phosphatidylglycerol</td>
| + | |
− | </tr>
| + | |
− | <tr>
| + | |
− | <td>Seekercin C</td>
| + | |
− | <td>Phosphatidylinositol</td>
| + | |
− | </tr>
| + | |
− | </tbody>
| + | |
− | </table>
| + | |
| </div> | | </div> |
− | </div>
| |
− | <br/><br/>
| |
− | <div class="">
| |
− | By instilling a particular microvolume of liquid into the upper
| |
− | airways and moving the plug by programmed air ventilation into
| |
− | the desired region of the lung, the aqueous liquid containing
| |
− | soluble drugs can be delivered into targeted branches of the
| |
− | lung airway and deposited onto the lung epithelium .
| |
− | </div>
| |
− | <br/><br/>
| |
− | <div class="">
| |
− | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/8/84/T--IIT_Roorkee--Poster_images--poster-content--poster_implementation_2.jpg"/>
| |
− | </div>
| |
− | <br/><br/>
| |
− | <div class="">
| |
− | We researched and decided on delivery of pyocins through
| |
− | nebulizers however, in India there is a disproportionately large
| |
− | problem with VAPs in the Newborn Intensive Care Units.
| |
− | <br/>
| |
− | (NICU) (60k+ deaths per year).
| |
| <br/><br/> | | <br/><br/> |
− | On seeking an expert opinion from a Doctor (NICU/VAP | + | <div class=""> |
− | specialist), he pointed out that neonates, especially preterm,
| + | <div class="table-responsive"> |
− | have underdeveloped lungs that are too delicate for effective
| + | <table class="table table-hover table-bordered"> |
− | nebulizer based treatment. | + | <thead class="thead-dark"> |
| + | <tr> |
| + | <th scope="col"> |
| + | <b>Mucolytics:</b> Carbocisteine, Erdosteine. |
| + | </th> |
| + | <th scope="col"> |
| + | <b>Bronchodilators:</b>Beta-2 agonists, |
| + | Anticholinergics, Theophylline |
| + | </th> |
| + | </tr> |
| + | </thead> |
| + | <tbody> |
| + | <tr> |
| + | <td>Seekercin A</td> |
| + | <td>di-Palmitoylphosphatidylcholine (DPPC)</td> |
| + | </tr> |
| + | <tr> |
| + | <td>Seekercin B</td> |
| + | <td>Phosphatidylglycerol</td> |
| + | </tr> |
| + | <tr> |
| + | <td>Seekercin C</td> |
| + | <td>Phosphatidylinositol</td> |
| + | </tr> |
| + | </tbody> |
| + | </table> |
| + | </div> |
| + | </div> |
| <br/><br/> | | <br/><br/> |
− | A big drawback of nebulizer therapy is its poor efficiency of | + | <div class=""> |
− | delivery, much of the dose is lost in the ETT (mist deposition
| + | By instilling a particular microvolume of liquid into the upper |
− | on the walls, medicine does not get misty well, etc.). Drug loss
| + | airways and moving the plug by programmed air ventilation into |
− | is no longer a concern when administering the bolus dose, since
| + | the desired region of the lung, the aqueous liquid containing |
− | the substance itself is injected into the lungs, taking the drug
| + | soluble drugs can be delivered into targeted branches of the |
− | with it. | + | lung airway and deposited onto the lung epithelium . |
| + | </div> |
| <br/><br/> | | <br/><br/> |
− | As observed in in-vivo studies, our rapid and efficient delivery | + | <div class=""> |
− | of bolus-injected surfactant solutions containing
| + | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/8/84/T--IIT_Roorkee--Poster_images--poster-content--poster_implementation_2.jpg"/> |
− | surfactant-associated proteins such as SP-A to the alveoli shows
| + | </div> |
− | a strong precedent for delivery of Seekercin is also more likely
| + | |
− | to ensure the delivery of high doses (10 ^ 12 pyocins per ml)
| + | |
− | needed for successful treatment. The dose will easily enter the
| + | |
− | alveoli, and it is predicted that changes will be observed | + | |
− | within seconds to minutes.
| + | |
| <br/><br/> | | <br/><br/> |
| + | <div class=""> |
| + | We researched and decided on delivery of pyocins through |
| + | nebulizers however, in India there is a disproportionately large |
| + | problem with VAPs in the Newborn Intensive Care Units. |
| + | <br/> |
| + | (NICU) (60k+ deaths per year). |
| + | <br/><br/> |
| + | On seeking an expert opinion from a Doctor (NICU/VAP |
| + | specialist), he pointed out that neonates, especially preterm, |
| + | have underdeveloped lungs that are too delicate for effective |
| + | nebulizer based treatment. |
| + | <br/><br/> |
| + | A big drawback of nebulizer therapy is its poor efficiency of |
| + | delivery, much of the dose is lost in the ETT (mist deposition |
| + | on the walls, medicine does not get misty well, etc.). Drug loss |
| + | is no longer a concern when administering the bolus dose, since |
| + | the substance itself is injected into the lungs, taking the drug |
| + | with it. |
| + | <br/><br/> |
| + | As observed in in-vivo studies, our rapid and efficient delivery |
| + | of bolus-injected surfactant solutions containing |
| + | surfactant-associated proteins such as SP-A to the alveoli shows |
| + | a strong precedent for delivery of Seekercin is also more likely |
| + | to ensure the delivery of high doses (10 ^ 12 pyocins per ml) |
| + | needed for successful treatment. The dose will easily enter the |
| + | alveoli, and it is predicted that changes will be observed |
| + | within seconds to minutes. |
| + | <br/><br/> |
| + | </div> |
| </div> | | </div> |
| </div> | | </div> |
Line 884: |
Line 931: |
| <div class="text"> | | <div class="text"> |
| <h3 class="wiki-h wiki-h3">Wet Lab</h3> | | <h3 class="wiki-h wiki-h3">Wet Lab</h3> |
− | <br/><br/> | + | <br/> |
| Initial experiments were performed in March but had to be | | Initial experiments were performed in March but had to be |
| aborted due to the pandemic and closing of our institute. We | | aborted due to the pandemic and closing of our institute. We |
| have laid out contingency plans for multiple scenarios based on | | have laid out contingency plans for multiple scenarios based on |
| the expected results of our wet lab experiments. | | the expected results of our wet lab experiments. |
− | <br/><br/> | + | <br/><br/><br/> |
| <h3 class="wiki-h wiki-h3">Dry Lab</h3> | | <h3 class="wiki-h wiki-h3">Dry Lab</h3> |
− | <br/><br/> | + | <br/> |
− | <div class="row"> | + | <div class="flex-row"> |
− | <div class="section quarter"> | + | <div class="img-third"> |
| <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/3/3f/T--IIT_Roorkee--Poster_images--poster-content--poster_results1.jpg"/> | | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/3/3f/T--IIT_Roorkee--Poster_images--poster-content--poster_results1.jpg"/> |
| </div> | | </div> |
− | <div class="section three_quarters"> | + | <div class=""> |
| <b> Root Mean Square Deviation </b> | | <b> Root Mean Square Deviation </b> |
| <br/> | | <br/> |
Line 909: |
Line 956: |
| </div> | | </div> |
| </div> | | </div> |
− | <div class="row"> | + | <br/> |
− | <div class="section quarter"> | + | <div class="flex-row"> |
| + | <div class="img-third"> |
| <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/f/f7/T--IIT_Roorkee--Poster_images--poster-content--poster_results2.jpg"/> | | <img alt="" class="poster-content-image poster-content-image-full" src="https://static.igem.org/mediawiki/2020/f/f7/T--IIT_Roorkee--Poster_images--poster-content--poster_results2.jpg"/> |
| </div> | | </div> |
− | <div class="section three_quarters"> | + | <div class=""> |
| <b> Ramachandran Plot </b> | | <b> Ramachandran Plot </b> |
| <br/> | | <br/> |
Line 928: |
Line 976: |
| </div> | | </div> |
| </div> | | </div> |
− | <br/><br/>
| |
− | <br/>
| |
| <br/><br/> | | <br/><br/> |
| <div class="table-responsive"> | | <div class="table-responsive"> |
Line 1,081: |
Line 1,127: |
| <li class="wiki-li"> | | <li class="wiki-li"> |
| Scholl, D. and Martin, D.W., 2008. Antibacterial efficacy of | | Scholl, D. and Martin, D.W., 2008. Antibacterial efficacy of |
− | R-type pyocins towards Pseudomonas aeruginosa in a murine | + | R-type pyocins towards <i>Pseudomonas aeruginosa</i> in a |
− | peritonitis model. Antimicrobial agents and chemotherapy, | + | murine peritonitis model. Antimicrobial agents and |
− | 52(5), pp.1647-1652. | + | chemotherapy, 52(5), pp.1647-1652. |
| </li> | | </li> |
| <li class="wiki-li"> | | <li class="wiki-li"> |